Share on StockTwits

Illumina (NASDAQ:ILMN) SVP Christian O. Henry sold 10,000 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $172.60, for a total transaction of $1,726,000.00. Following the sale, the senior vice president now directly owns 28,519 shares of the company’s stock, valued at approximately $4,922,379. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Illumina (NASDAQ:ILMN) traded up 1.25% on Wednesday, hitting $170.86. The stock had a trading volume of 1,319,333 shares. Illumina has a 52 week low of $72.13 and a 52 week high of $183.30. The stock has a 50-day moving average of $160.2 and a 200-day moving average of $146.. The company has a market cap of $21.938 billion and a price-to-earnings ratio of 118.67. Illumina also saw a large drop in short interest during the month of June. As of June 13th, there was short interest totalling 10,265,824 shares, a drop of 41.3% from the May 30th total of 17,495,888 shares. Based on an average daily trading volume, of 2,518,211 shares, the short-interest ratio is presently 4.1 days. Approximately 8.1% of the shares of the company are short sold.

Illumina (NASDAQ:ILMN) last released its earnings data on Tuesday, April 22nd. The company reported $0.46 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.45 by $0.01. The company had revenue of $421.00 million for the quarter, compared to the consensus estimate of $391.50 million. During the same quarter in the prior year, the company posted $0.46 earnings per share. The company’s quarterly revenue was up 27.2% on a year-over-year basis. Analysts expect that Illumina will post $2.16 EPS for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of Illumina from a “neutral” rating to an “outperform” rating in a research note on Tuesday. They now have a $205.00 price target on the stock. Separately, analysts at Ned Davis Research upgraded shares of Illumina from a “sell” rating to a “neutral” rating in a research note on Monday, April 28th. Finally, analysts at Maxim Group upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research note on Wednesday, April 23rd. They now have a $205.00 price target on the stock. Seven investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $146.71.

Illumina, Inc (NASDAQ:ILMN) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.